Jagsonpal Pharmaceuticals Ltd Q2FY22 PAT at Rs. 7.30 crore

The Board of Directors of Jagsonpal Pharmaceuticals Limited, at its meeting held today have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021.

For the quarter ended September 30, 2021(Q2 FY2022), the company's total income was ₹ 59.7736 crore, against ₹56.7662 crore in the corresponding quarter of the previous year (YoY) and ₹60.8204 crore in previous quarter (QoQ).

For the quarter ended September 30, 2021(Q2 FY2022), the company's net profit / (loss) was ₹7.3074 crore, against ₹4.0087 crore in the corresponding quarter of the previous year (YoY) and ₹6.8481 crore in previous quarter (QoQ).

For the quarter ended September 30, 2021(Q2 FY2022), the company's Earnings Per Share (EPS) was ₹2.79, against ₹1.53 in the corresponding quarter of the previous year (YoY) and ₹2.61 in previous quarter (QoQ).

Financials	Q2 FY2022	Q1 FY2022	QoQ % Change	Q2 FY2021	YoY % Change
Total Income	₹ 59.7736 crs	₹60.8204 crs	-1.72%	₹56.7662 crs	5.30%
Net Profit	₹7.3074 crs	₹6.8481 crs	6.71%	₹4.0087 crs	82.29 %
EPS	₹2.79	₹2.61	6.90%	₹1.53	82.35%

For the 6 Months period ended September 30, 2021(Half Year Ended FY 2022), the company's total income was ₹120.5940 crore, against ₹89.2028 crore in the previous year (YoY) (Half Year Ended FY 2021).

The net profit / (loss) was at ₹14.1555 crore for the 6 Months period ended September 30, 2021 (Half Year Ended FY 2022), compared to ₹6.5290 crore in the previous year (YoY) (Half Year Ended FY 2021).

The Earnings Per Share stood at ₹5.40 for the 6 Months period ended September 30, 2021 (Half Year Ended FY 2022), against ₹2.49 in the previous year (YoY) (Half Year Ended FY 2021).

Financials	Half Year Ended FY2022	Half Year Ended FY2021	% Change
Total Income	₹120.5940 crs	₹89.2028 crs	35.19%
Net Profit	₹14.1555 crs	₹6.5290 crs	116.81%
EPS	₹5.40	₹2.49	116.87%

Commenting on the performance, Mr. R.P.S. Kochhar, Chairman & Managing Director, Jagsonpal Pharmaceuticals said, "We have delivered another steady quarter of revenues while our EBITDA margins continue to show consistency. As mentioned in the last quarter, our efforts on product rationalization, focus on high margin products, cost control initiatives and improvement in operational matrix with better supply chain management have started yielding results. I would like to highlight that the Company has recorded an EBITDA of INR 207 mn in the first half of this fiscal against INR 235 mn reported for the whole year in fiscal 21 and INR 87 mn in H1FY21. We expect the momentum to continue in the H2 FY22 barring unforeseen circumstances.

The board has approved an Interim Dividend @ 80% per Equity Shares of face value of Rs. 5/-, which translates to Rs. 4 per equity share. The decision was taken by the board keeping in mind the excess cash in the balance sheet with no immediate capex plans in the horizon. The board will continue to assess the cash situation and reward shareholders after meeting all the needs of the Company.

In keeping with its strategy for growth, the Company has engaged Accenture to review and chalk out a business transformation plan with a focus on revenue growth, cost optimization and building organization enablers."

Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 162.20 as compared to the previous close of Rs. 162.45. The total number of shares traded during the day was 43291 in over 995 trades.

The stock hit an intraday high of Rs. 169.40 and intraday low of 160.00. The net turnover during the day was Rs. 7152768.00.

Source : Equity Bulls

Keywords

JagsonpalPharmaceuticals Q2FY22 H1FY22 ResultUpdate